Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COM701 Monotherapy and in Combination with Nivolumab in Advanced Solid Tumors
NCT03667716Phase 1Completed
- Sponsor
- Compugen Ltd.
- Start
- Sep 2018
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of COM701 in solid tumor (advanced stage) (4 arms), sponsored by Compugen Ltd. Primary endpoints: Incidence of subjects with Adverse Events and Dose-Limiting Toxicities at 28 days and Maximum Tolerated Dose and/or Recommended Dose for Expansion at 2 years. Started Sep 2018; status: completed.
02
Drugs
COM701
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03667716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03667716.